Loading…
Where Are We With the Management of Hypertension? From Science to Clinical Practice
The management of elevated blood pressure in patients at high cardiovascular risk is still a subject of debate. The authors review current international guidelines and results of large clinical trials and recent meta‐analyses to discuss the different approaches in patients at high risk for cardiovas...
Saved in:
Published in: | The journal of clinical hypertension (Greenwich, Conn.) Conn.), 2009-02, Vol.11 (2), p.66-73 |
---|---|
Main Authors: | , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c5096-745670e008bba96a26cee8acb8796d127aedc38da37c29cd66f463a98915db23 |
---|---|
cites | cdi_FETCH-LOGICAL-c5096-745670e008bba96a26cee8acb8796d127aedc38da37c29cd66f463a98915db23 |
container_end_page | 73 |
container_issue | 2 |
container_start_page | 66 |
container_title | The journal of clinical hypertension (Greenwich, Conn.) |
container_volume | 11 |
creator | Farsang, Csaba Naditch‐Brule, Lisa Avogaro, Angelo Östergren, Jan Verdecchia, Paolo Maggioni, Aldo Van De Borne, Philippe Lins, Robert Roca‐Cusachs, Alexandre |
description | The management of elevated blood pressure in patients at high cardiovascular risk is still a subject of debate. The authors review current international guidelines and results of large clinical trials and recent meta‐analyses to discuss the different approaches in patients at high risk for cardiovascular events. The different treatment options are considered in view of the modern approach and of the different classes of drugs (diuretics, angiotensin‐converting enzyme inhibitors, calcium channel blockers, β‐blockers, and angiotensin II receptor blockers) currently in use. A case report is presented as an illustration of the difficulties related to the management of high blood pressure in patients at increased risk. The benefits of the use of 2 medications that include an inhibitor of the renin‐angiotensin‐aldosterone system and a calcium channel blocker or a diuretic are discussed. Choosing the proper drugs and correct doses are important considerations for the long‐term management of hypertension. |
doi_str_mv | 10.1111/j.1751-7176.2008.00066.x |
format | article |
fullrecord | <record><control><sourceid>wiley_swepu</sourceid><recordid>TN_cdi_swepub_primary_oai_swepub_ki_se_559634</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>JCH066</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5096-745670e008bba96a26cee8acb8796d127aedc38da37c29cd66f463a98915db23</originalsourceid><addsrcrecordid>eNqNUe1KwzAUDaL4MX0FyQu05mNNGhBFhnOKorCBP0Oa3trMrh1pddvbm7kx9Z8hIZd7zzm5uQchTElMw7qYxlQmNJJUipgRksaEECHi5R463hX2Q5ywfiRC5gidtO2UkIRzRQ7REVWMMSHJMRq_luAB34TzGrbrStyVgJ9Mbd5gBnWHmwKPVnPwHdSta-prPPTNDI-tg9oC7ho8qFztrKnwize2cxZO0UFhqhbOtncPTYa3k8Eoeny-ux_cPEY2IUpEsp-EFiC0n2VGCcOEBUiNzVKpRE6ZNJBbnuaGS8uUzYUo-oIblSqa5BnjPRRtZNsFzD8yPfduZvxKN8bpbeo9RKCTRAneD_irDT5UZkE6fM6b6g_tb6V2pX5rPnUqJKeEBoF0I2B907Yeih2XEr32RU_1evx6PX699kV_-6KXgXr---0f4taIALjcABaugtW_hfXDYBQC_gXVvJ1V</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Where Are We With the Management of Hypertension? From Science to Clinical Practice</title><source>PubMed Central</source><creator>Farsang, Csaba ; Naditch‐Brule, Lisa ; Avogaro, Angelo ; Östergren, Jan ; Verdecchia, Paolo ; Maggioni, Aldo ; Van De Borne, Philippe ; Lins, Robert ; Roca‐Cusachs, Alexandre</creator><creatorcontrib>Farsang, Csaba ; Naditch‐Brule, Lisa ; Avogaro, Angelo ; Östergren, Jan ; Verdecchia, Paolo ; Maggioni, Aldo ; Van De Borne, Philippe ; Lins, Robert ; Roca‐Cusachs, Alexandre</creatorcontrib><description>The management of elevated blood pressure in patients at high cardiovascular risk is still a subject of debate. The authors review current international guidelines and results of large clinical trials and recent meta‐analyses to discuss the different approaches in patients at high risk for cardiovascular events. The different treatment options are considered in view of the modern approach and of the different classes of drugs (diuretics, angiotensin‐converting enzyme inhibitors, calcium channel blockers, β‐blockers, and angiotensin II receptor blockers) currently in use. A case report is presented as an illustration of the difficulties related to the management of high blood pressure in patients at increased risk. The benefits of the use of 2 medications that include an inhibitor of the renin‐angiotensin‐aldosterone system and a calcium channel blocker or a diuretic are discussed. Choosing the proper drugs and correct doses are important considerations for the long‐term management of hypertension.</description><identifier>ISSN: 1524-6175</identifier><identifier>EISSN: 1751-7176</identifier><identifier>DOI: 10.1111/j.1751-7176.2008.00066.x</identifier><identifier>PMID: 19222670</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Adrenergic beta-Antagonists - therapeutic use ; Angiotensin II Type 1 Receptor Blockers - therapeutic use ; Angiotensin-Converting Enzyme Inhibitors - therapeutic use ; Calcium Channel Blockers - therapeutic use ; Comorbidity ; Diabetes Mellitus - diagnosis ; Diabetes Mellitus - epidemiology ; Diet, Fat-Restricted ; Diet, Sodium-Restricted ; Disease Progression ; Diuretics - therapeutic use ; Drug Therapy, Combination ; Female ; Humans ; Hypertension - diagnosis ; Hypertension - epidemiology ; Hypertension - therapy ; Metabolic Syndrome - diagnosis ; Metabolic Syndrome - epidemiology ; Middle Aged ; Practice Guidelines as Topic ; Randomized Controlled Trials as Topic ; Review Paper ; Severity of Illness Index ; Treatment Outcome</subject><ispartof>The journal of clinical hypertension (Greenwich, Conn.), 2009-02, Vol.11 (2), p.66-73</ispartof><rights>2009 Wiley Periodicals, Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5096-745670e008bba96a26cee8acb8796d127aedc38da37c29cd66f463a98915db23</citedby><cites>FETCH-LOGICAL-c5096-745670e008bba96a26cee8acb8796d127aedc38da37c29cd66f463a98915db23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8673101/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8673101/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27903,27904,53770,53772</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19222670$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttp://kipublications.ki.se/Default.aspx?queryparsed=id:118282930$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>Farsang, Csaba</creatorcontrib><creatorcontrib>Naditch‐Brule, Lisa</creatorcontrib><creatorcontrib>Avogaro, Angelo</creatorcontrib><creatorcontrib>Östergren, Jan</creatorcontrib><creatorcontrib>Verdecchia, Paolo</creatorcontrib><creatorcontrib>Maggioni, Aldo</creatorcontrib><creatorcontrib>Van De Borne, Philippe</creatorcontrib><creatorcontrib>Lins, Robert</creatorcontrib><creatorcontrib>Roca‐Cusachs, Alexandre</creatorcontrib><title>Where Are We With the Management of Hypertension? From Science to Clinical Practice</title><title>The journal of clinical hypertension (Greenwich, Conn.)</title><addtitle>J Clin Hypertens (Greenwich)</addtitle><description>The management of elevated blood pressure in patients at high cardiovascular risk is still a subject of debate. The authors review current international guidelines and results of large clinical trials and recent meta‐analyses to discuss the different approaches in patients at high risk for cardiovascular events. The different treatment options are considered in view of the modern approach and of the different classes of drugs (diuretics, angiotensin‐converting enzyme inhibitors, calcium channel blockers, β‐blockers, and angiotensin II receptor blockers) currently in use. A case report is presented as an illustration of the difficulties related to the management of high blood pressure in patients at increased risk. The benefits of the use of 2 medications that include an inhibitor of the renin‐angiotensin‐aldosterone system and a calcium channel blocker or a diuretic are discussed. Choosing the proper drugs and correct doses are important considerations for the long‐term management of hypertension.</description><subject>Adrenergic beta-Antagonists - therapeutic use</subject><subject>Angiotensin II Type 1 Receptor Blockers - therapeutic use</subject><subject>Angiotensin-Converting Enzyme Inhibitors - therapeutic use</subject><subject>Calcium Channel Blockers - therapeutic use</subject><subject>Comorbidity</subject><subject>Diabetes Mellitus - diagnosis</subject><subject>Diabetes Mellitus - epidemiology</subject><subject>Diet, Fat-Restricted</subject><subject>Diet, Sodium-Restricted</subject><subject>Disease Progression</subject><subject>Diuretics - therapeutic use</subject><subject>Drug Therapy, Combination</subject><subject>Female</subject><subject>Humans</subject><subject>Hypertension - diagnosis</subject><subject>Hypertension - epidemiology</subject><subject>Hypertension - therapy</subject><subject>Metabolic Syndrome - diagnosis</subject><subject>Metabolic Syndrome - epidemiology</subject><subject>Middle Aged</subject><subject>Practice Guidelines as Topic</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Review Paper</subject><subject>Severity of Illness Index</subject><subject>Treatment Outcome</subject><issn>1524-6175</issn><issn>1751-7176</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><recordid>eNqNUe1KwzAUDaL4MX0FyQu05mNNGhBFhnOKorCBP0Oa3trMrh1pddvbm7kx9Z8hIZd7zzm5uQchTElMw7qYxlQmNJJUipgRksaEECHi5R463hX2Q5ywfiRC5gidtO2UkIRzRQ7REVWMMSHJMRq_luAB34TzGrbrStyVgJ9Mbd5gBnWHmwKPVnPwHdSta-prPPTNDI-tg9oC7ho8qFztrKnwize2cxZO0UFhqhbOtncPTYa3k8Eoeny-ux_cPEY2IUpEsp-EFiC0n2VGCcOEBUiNzVKpRE6ZNJBbnuaGS8uUzYUo-oIblSqa5BnjPRRtZNsFzD8yPfduZvxKN8bpbeo9RKCTRAneD_irDT5UZkE6fM6b6g_tb6V2pX5rPnUqJKeEBoF0I2B907Yeih2XEr32RU_1evx6PX699kV_-6KXgXr---0f4taIALjcABaugtW_hfXDYBQC_gXVvJ1V</recordid><startdate>200902</startdate><enddate>200902</enddate><creator>Farsang, Csaba</creator><creator>Naditch‐Brule, Lisa</creator><creator>Avogaro, Angelo</creator><creator>Östergren, Jan</creator><creator>Verdecchia, Paolo</creator><creator>Maggioni, Aldo</creator><creator>Van De Borne, Philippe</creator><creator>Lins, Robert</creator><creator>Roca‐Cusachs, Alexandre</creator><general>Blackwell Publishing Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope><scope>ADTPV</scope><scope>AOWAS</scope><scope>D8T</scope><scope>ZZAVC</scope></search><sort><creationdate>200902</creationdate><title>Where Are We With the Management of Hypertension? From Science to Clinical Practice</title><author>Farsang, Csaba ; Naditch‐Brule, Lisa ; Avogaro, Angelo ; Östergren, Jan ; Verdecchia, Paolo ; Maggioni, Aldo ; Van De Borne, Philippe ; Lins, Robert ; Roca‐Cusachs, Alexandre</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5096-745670e008bba96a26cee8acb8796d127aedc38da37c29cd66f463a98915db23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Adrenergic beta-Antagonists - therapeutic use</topic><topic>Angiotensin II Type 1 Receptor Blockers - therapeutic use</topic><topic>Angiotensin-Converting Enzyme Inhibitors - therapeutic use</topic><topic>Calcium Channel Blockers - therapeutic use</topic><topic>Comorbidity</topic><topic>Diabetes Mellitus - diagnosis</topic><topic>Diabetes Mellitus - epidemiology</topic><topic>Diet, Fat-Restricted</topic><topic>Diet, Sodium-Restricted</topic><topic>Disease Progression</topic><topic>Diuretics - therapeutic use</topic><topic>Drug Therapy, Combination</topic><topic>Female</topic><topic>Humans</topic><topic>Hypertension - diagnosis</topic><topic>Hypertension - epidemiology</topic><topic>Hypertension - therapy</topic><topic>Metabolic Syndrome - diagnosis</topic><topic>Metabolic Syndrome - epidemiology</topic><topic>Middle Aged</topic><topic>Practice Guidelines as Topic</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Review Paper</topic><topic>Severity of Illness Index</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Farsang, Csaba</creatorcontrib><creatorcontrib>Naditch‐Brule, Lisa</creatorcontrib><creatorcontrib>Avogaro, Angelo</creatorcontrib><creatorcontrib>Östergren, Jan</creatorcontrib><creatorcontrib>Verdecchia, Paolo</creatorcontrib><creatorcontrib>Maggioni, Aldo</creatorcontrib><creatorcontrib>Van De Borne, Philippe</creatorcontrib><creatorcontrib>Lins, Robert</creatorcontrib><creatorcontrib>Roca‐Cusachs, Alexandre</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><collection>SwePub</collection><collection>SwePub Articles</collection><collection>SWEPUB Freely available online</collection><collection>SwePub Articles full text</collection><jtitle>The journal of clinical hypertension (Greenwich, Conn.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Farsang, Csaba</au><au>Naditch‐Brule, Lisa</au><au>Avogaro, Angelo</au><au>Östergren, Jan</au><au>Verdecchia, Paolo</au><au>Maggioni, Aldo</au><au>Van De Borne, Philippe</au><au>Lins, Robert</au><au>Roca‐Cusachs, Alexandre</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Where Are We With the Management of Hypertension? From Science to Clinical Practice</atitle><jtitle>The journal of clinical hypertension (Greenwich, Conn.)</jtitle><addtitle>J Clin Hypertens (Greenwich)</addtitle><date>2009-02</date><risdate>2009</risdate><volume>11</volume><issue>2</issue><spage>66</spage><epage>73</epage><pages>66-73</pages><issn>1524-6175</issn><eissn>1751-7176</eissn><abstract>The management of elevated blood pressure in patients at high cardiovascular risk is still a subject of debate. The authors review current international guidelines and results of large clinical trials and recent meta‐analyses to discuss the different approaches in patients at high risk for cardiovascular events. The different treatment options are considered in view of the modern approach and of the different classes of drugs (diuretics, angiotensin‐converting enzyme inhibitors, calcium channel blockers, β‐blockers, and angiotensin II receptor blockers) currently in use. A case report is presented as an illustration of the difficulties related to the management of high blood pressure in patients at increased risk. The benefits of the use of 2 medications that include an inhibitor of the renin‐angiotensin‐aldosterone system and a calcium channel blocker or a diuretic are discussed. Choosing the proper drugs and correct doses are important considerations for the long‐term management of hypertension.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>19222670</pmid><doi>10.1111/j.1751-7176.2008.00066.x</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1524-6175 |
ispartof | The journal of clinical hypertension (Greenwich, Conn.), 2009-02, Vol.11 (2), p.66-73 |
issn | 1524-6175 1751-7176 |
language | eng |
recordid | cdi_swepub_primary_oai_swepub_ki_se_559634 |
source | PubMed Central |
subjects | Adrenergic beta-Antagonists - therapeutic use Angiotensin II Type 1 Receptor Blockers - therapeutic use Angiotensin-Converting Enzyme Inhibitors - therapeutic use Calcium Channel Blockers - therapeutic use Comorbidity Diabetes Mellitus - diagnosis Diabetes Mellitus - epidemiology Diet, Fat-Restricted Diet, Sodium-Restricted Disease Progression Diuretics - therapeutic use Drug Therapy, Combination Female Humans Hypertension - diagnosis Hypertension - epidemiology Hypertension - therapy Metabolic Syndrome - diagnosis Metabolic Syndrome - epidemiology Middle Aged Practice Guidelines as Topic Randomized Controlled Trials as Topic Review Paper Severity of Illness Index Treatment Outcome |
title | Where Are We With the Management of Hypertension? From Science to Clinical Practice |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T16%3A16%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wiley_swepu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Where%20Are%20We%20With%20the%20Management%20of%20Hypertension?%20From%20Science%20to%20Clinical%20Practice&rft.jtitle=The%20journal%20of%20clinical%20hypertension%20(Greenwich,%20Conn.)&rft.au=Farsang,%20Csaba&rft.date=2009-02&rft.volume=11&rft.issue=2&rft.spage=66&rft.epage=73&rft.pages=66-73&rft.issn=1524-6175&rft.eissn=1751-7176&rft_id=info:doi/10.1111/j.1751-7176.2008.00066.x&rft_dat=%3Cwiley_swepu%3EJCH066%3C/wiley_swepu%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c5096-745670e008bba96a26cee8acb8796d127aedc38da37c29cd66f463a98915db23%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/19222670&rfr_iscdi=true |